Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

NLM Logo

Irinotecan MeSH Descriptor Data 2026


MeSH Heading
Irinotecan
Tree Number(s)
D03.132.151.425
Unique ID
D000077146
RDF Unique Identifier
http://id.nlm.nih.gov/mesh/D000077146
Scope Note
A semisynthetic camptothecin derivative that inhibits DNA TOPOISOMERASE I to prevent nucleic acid synthesis during S PHASE. It is used as an antineoplastic agent for the treatment of COLORECTAL NEOPLASMS and PANCREATIC NEOPLASMS.
Entry Term(s)
7-Ethyl-10-hydroxycamptothecin
CPT 11
CPT-11
Camptosar
Camptothecin-11
Irinotecan Hydrochloride
Irrinotecan
NK012 Compound
SN 38
SN 38 11
SN-38
SN-38-11
Pharm Action
Topoisomerase I Inhibitors
Registry Numbers
7673326042
0
0H43101T0J
042LAQ1IIS
Related Numbers
042LAQ1IIS
0H43101T0J
CAS Type 1 Name
(1,4'-Bipiperidine)-1'-carboxylic acid, (4S)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano(3',4':6,7)indolizino(1,2-b)quinolin-9-yl ester
Public MeSH Note
2019; IRINOTECAN was indexed under CAMPTOTHECIN 1987-2018
History Note
2019 (1987)
Date Introduced
2019/01/01
Last Updated
2019/01/01
Irinotecan Preferred
SN 38 11 Narrower
7-Ethyl-10-hydroxycamptothecin Narrower
SN 38 Narrower
Irinotecan Hydrochloride Narrower
NK012 Compound Narrower
Camptosar Narrower
CPT-11 Narrower
page delivered in 0.141s